Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo.

Leqembi is supplied as a preservative-free solution in single-dose vials of 500mg/5mL and 200mg/2mL. Treatment is administered by intravenous infusion once every 2 weeks. The Company say it will ...

LEQEMBI contributed $96 million in sales, reflecting an 11% sequential growth. Global SKYCLARYS revenue reached $124 million, up 21% from Q4 2024, driven by geographic expansion and patient growth.

The mean CDR-SB score at baseline was approximately 3.2 in both groups. The study found that after 18 months of treatment, the CDR-SB score in patients treated with Leqembi increased by 1.21 ...

Eisai further investigated Clarity AD with a view to showing Leqembi can help chart a “relative” preservation of health-related quality of life and caregiver burden, as reported by patients ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it. The infused treatment ...

An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving the ...

LEQEMBI is also approved and being marketed in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and Great Britain. LEQEMBI's approval is based on the large global ...

While the drug cannot stop Alzheimer’s from getting worse, data suggests that Leqembi may be able to slow cognitive decline by five months over a period of 18 months for people with mild symptoms.

With the launch of intravenous Leqembi (lecanemab-irmb) for Alzheimer’s disease (AD) underway, Priya Singhal, Biogen Inc.’s head of development and interim head of research, said the firm, along with ...